Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy

Conrad C. Weihl, Anne M. Connolly, Alan Pestronk

Research output: Contribution to journalArticlepeer-review

103 Scopus citations

Abstract

Spinal muscular atrophy (SMA) is a recessively inherited motor neuron disease caused by deficient survival motor neuron (SMN) protein. Valproate increases SMN protein in vitro by increasing transcription of SMN2 genes. The authors treated seven adult patients with SMA type III/IV with valproate for a mean duration of 8 months. The treated patients with SMA had increased quantitative muscle strength and subjective function. Further trials of valproate treatment for SMA type III/IV are warranted.

Original languageEnglish
Pages (from-to)500-501
Number of pages2
JournalNeurology
Volume67
Issue number3
DOIs
StatePublished - Aug 2006

Fingerprint

Dive into the research topics of 'Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy'. Together they form a unique fingerprint.

Cite this